Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$5.5MCash on Hand
3.2mo Cash Runway
Follow JAGX by emailGet an email when JAGX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about JAGX, unsubscribe in one click. Privacy
📣 What JAGX Says Is Next
mid-2027 · “Jaguar’s intestinal failure program is expected to continue to provide clinical milestones, including a planned New Drug Application (NDA) filing for crofelemer for MVID in mid-2027.” The payment date for the Special Stock Dividend is October 15, 2026, two days after the Record Date.”
Company press release, Oct 5, 2026 · SEC filing
first half of 2027 · “Jaguar is targeting Breakthrough Therapy designation for crofelemer for the indication of microvillus inclusion disease (MVID), with a planned filing of an NDA (New Drug Application) with the U.S. Food and Drug Administration (FDA) for this indication in the first half of 2027.” MVID is a lethal and ultrarare genetic pediatric disorder that causes intestinal failure.”
Company press release, Jun 25, 2026 · SEC filing
mid-2027 · “We continue to sharply focus on our pivotal-stage development program for our novel proprietary powder-for-oral-solution formulation of crofelemer for rare intestinal failure indications, targeting an NDA in mid-2027, and on identifying a development and commercialization partner for this program.””
Company press release, May 27, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 9, 2026 ·
Financing Jaguar Health filed a shelf prospectus to sell up to $75,000,000 of common stock, preferred stock, warrants, subscription rights or units, with terms to be set in later supplements. The voting common stock last sold at $0.8841 on Nasdaq on November 2, 2026. Form 424B3 · SEC filing
Nov 9, 2026 ·
Financing Jaguar Health filed a prospectus supplement for an at-the-market offering of up to $75,000,000 of common stock through Ladenburg Thalmann, with a 3% commission. The stock last closed at $0.4988 on November 4, 2026. Form 424B5 · SEC filing
Nov 6, 2026 ·
Shareholder vote Jaguar Health stockholders approved all six proposals at a November 6, 2026 special meeting, including a reverse stock split at a ratio between 1-for-2 and 1-for-150 and a reduction of the ELOC floor price from $16.50 to $1.10 per share. Form 8-K · SEC filing · Press release
Nov 3, 2026 ·
Jaguar Health's Series R preferred stock automatically converted into common stock on November 2, 2026, at five common shares per preferred share, following the October 15 special dividend of Series O preferred. After conversion there were 13,345,986 common shares outstanding. Form 8-K · SEC filing
Oct 28, 2026 ·
Shareholder vote Jaguar Health supplemented its proxy for a November 6, 2026 special meeting to disclose a Share Reserve Adjustment under its 2014 Stock Incentive Plan. Following a Series R Preferred Stock dividend, the Compensation Committee approved a six-fold increase in shares available under the plan. Form 8-K · SEC filing
Oct 8, 2026 ·
Shareholder vote Special meeting on Nov 6, 2026 asks holders to approve a 1-for-2 to 1-for-150 reverse split, a reduction of the ELOC floor price from $16.50 to $1.10, warrant repricing to $1.00, Series Q preferred and CVP debt share issuance, a 2014 Plan increase to 378,859 shares, and adjournment. Form DEF 14A · SEC filing
Oct 5, 2026 ·
Financing Jaguar Health amended royalty interests with Uptown Capital and Streeterville, pushing monthly payments from October 1, 2026 to January 1, 2027 with a $750,000 monthly minimum. A Streeterville note maturity moved to January 1, 2027. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jun 2028 · Phase 1/2 · Recruiting · JAG201 Gene Therapy Study in Children & Adults With SHANK3 Haploinsufficiency Registry primary completion date, not a results date
💰 Cash Runway & Dilution Risk
JAGX holds $5.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $5.1M/quarter from operations,
an estimated runway of 3.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:30 · Moderate
Cash runway 34 months
ATM program on file since Sep 2026 +15
Shelf registration (S-3, Oct 2026) +10
Going-concern doubt in the latest 10-Q +15These conditions, along with recurring operating losses and an accumulated deficit, raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the issuance of these consolidated financial statements.10-Q, Nov 2026
Raised after last reported balance sheet (Nov 2026) -10
Share count 171,350,166 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full JAGX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for JAGX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.